Please enable JavaScript.
Coggle requires JavaScript to display documents.
Treatment of Diabetes - Coggle Diagram
Treatment of Diabetes
Pharmacotherapy
Metformin
Mechanism of Action
Potentiation of insulin signalling: Downstream effects result in Decreased lipid synethesis, decrease gluconeogenesis and increase action of GLUT-4 and glucose uptake/synthesis
Benefits: Rare hypoglycemia, weight neutral, improved CV risk factors, inexpensive
Risks: GI side effects, Renal: reduce dose required with declining eGFR, B12 deficiency
GLP1RA
Mechanism of Action
In response to food, insulin secretion increases, glucagon secretion decreases, satiety increases and gastric emptying decreases
Incretin Hormones: GLP1, GIP
Benefits
Rare hypoglycemia, weight loss, CVD benefit
Risks: GI side effects, mainly SC, rare causes of pancreatitis, increase risk of medullary thyroid cnacer
SGLT2 Inhibitors
-
Benefits
Weigt loss, CVD benefit, Decreased hospitalization for heart failure
Risks
Mycotic Genital infections, hypotension, rare cases of ketoacidosis
DPP4 Inhibitors
Mechanism of Action
Inhibits breakdown of endogenous GLP1 and GIP which leads to increased signalling leading to increased insulin
Benefits: Weight neutral, hypoglycaemia low risk, CV event neutral
Risks: GI Side effects, rare cases of pancreatitis
Insulin Secretagogues
Bind to sides of KATP (channel), promotes depolarization -> Ca influx -> Insulin Release
Sulfonylureas
-
Risks: Weight gain, hypoglycemia
Meglitinides
Benefits: Decrease A1C, better postprandial coverage, safe in renal impairment
Risks: Weight gain, Hypoglycaemia, Moderate cost
-
Thiazolidinediones
-
Benefits
Lower A1C, Low risk of hypoglycemia, Reduce stroke risk, reduces fatty liver
Risks: Weight gain, hypoglycemia, peripheral edema, Osteopenia/Fractures
-
-